Remove Download Remove Patient Care Remove Pharmaceutical Companies
article thumbnail

The Complete Guide to Pharmaceutical Detailing

Viseven

Pharmaceutical detailing is the most time-tested marketing format in the medical content world. Old-timer sales reps should remember how pharmaceutical companies reckoned face-to-face (F2F) visits with doctors as the most effective approach to achieving their sales targets. What is Pharmaceutical Detailing?

article thumbnail

From agility to AI: Safeguarding against supply chain disruptions

Pharmaceutical Technology

Any reduced availability of medicines has a significant impact on patient care. As visibility diminishes, mismanagement of the supply chain can not only lead to revenue and reputational damage for manufacturers but more importantly, loss of life for patients. The CMO solution.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sandoz targets barriers to biosimilar accessibility with latest initiative

Pharmaceutical Technology

Generic and biosimilar pharmaceutical company and Novartis subsidiary Sandoz announced its plan to accelerate patient access to biosimilars. In a 15 June statement, Sandoz said that it hoped the Act4Biosimilars action plan will provide actionable solutions to overcome barriers preventing patient access to biosimilars.

article thumbnail

Influence of 5G on Healthcare

Viseven

These improvements enable 5G networks to reduce download and upload times, enhance reliability, and provide stronger connectivity. Pharmaceutical companies Pharmaceutical companies can transform their approaches to clinical trials with the help of 5G networks.

article thumbnail

Legal challenges put off label use of gender affirming care drugs in jeopardy

Pharmaceutical Technology

Barry DeCoster, PhD, an associate professor of bioethics at the University of Michigan, describes gender affirming care as “safe and effective” for most patients. Most drugs used here are prescribed off-label, and experts say pharmaceutical companies remain hesitant to conduct clinical trials studying gender-affirming care.

Labelling 144